Skip Ribbon Commands
Skip to main content
Navigate Up
Sign In
Skip Navigation LinksCVMBS Home > Veterinary Teaching Hospital > For Veterinarians > Clinical Trials > The Effects of Topical Naltrexone on Corneal Sensitivity and Tear Production in Diabetic Dogs Clinical Trial
The Effects of Topical Naltrexone on Corneal Sensitivity and Tear Production in Diabetic Dogs Clinical Trial

Return to the Clinical Trials Homepage

 

Who qualifies:

All dogs must be confirmed diabetics based on previous history and blood work (documented glucosuria and blood glucose ≥200mg/dl) and have received insulin therapy for diabetes mellitus for at least two months prior to entering the study. Exclusion criteria include brachycephalic breed (pugs, bulldogs, boxers, etc.), significant systemic disease other than diabetes mellitus, pregnant or lactating, Schirmer tear test less than 5 mm wetting per minute, current treatment with topical ophthalmic medication, any current ocular disease requiring treatment.

More information:

Our intent is to demonstrate the effectiveness of topically applied naltrexone in increasing the corneal sensitivity, tear production and tear film break up time in diabetic dogs. If this response can be documented, topical naltrexone could be used to improve the quality of vision and decrease suffering due to corneal disease in diabetic dogs.

To enroll: 

Interested participants can learn more by contacting Dr. Trevor Arnold; (970) 297-5000